Amit Sud

Amit Sud

Auto-generated profile, based on publicly available information

Amit Sud

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
ASAmit Sud
Amit Sud
BTBethany Torr
Bethany Torr
MJMichael E Jones
Michael E Jones
JBJohn Broggio
John Broggio
SSStephen Scott
Stephen Scott
CTClare Turnbull
Clare Turnbull

1 August 2020 in Annals of Oncology
Verified
Journal Article
Open access
ASA. Sud
A. Sud
MJM.E. Jones
M.E. Jones
JBJ. Broggio
J. Broggio
CLC. Loveday
C. Loveday
BTB. Torr
B. Torr
CTC. Turnbull
C. Turnbull
Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival. We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of 3 and 6 months and periods of disruption of 1 and 2 years. Using health care resource costing, we contextualise attributable lives saved and life-years gained (LYGs) from cancer surgery to equivalent volumes of COVID-19 hospitalisations. Per year, 94 912 resections for major cancers result in 80 406 long-term survivors and 1 717 051 LYGs. Per-patient delay of 3/6 months would cause attributable death of 4755/10 760 of these individuals with loss of 92 214/208 275 life-years, respectively. For cancer surgery, average LYGs per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of 3/6 months (an average loss of 0.97/2.19 LYGs per patient), respectively. Taking into account health care resource units (HCRUs), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of 3/6 months. For 94 912 hospital COVID-19 admissions, there are 482 022 LYGs requiring 1 052 949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs. Modest delays in surgery for cancer incur significant impact on survival. Delay of 3/6 months in surgery for incident cancers would mitigate 19%/43% of LYGs, respectively, by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59%, respectively, when considering RALYGs. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued.

13 October 2017 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
ASAmit Sud
Amit Sud
BKBen Kinnersley
Ben Kinnersley
Richard HoulstonRichard Houlston
Richard Houlston

14 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PLPhilip J. Law
Philip J. Law
MTMaria Timofeeva
Maria Timofeeva
Ceres Fernández-RozadillaCeres Fernández-Rozadilla
Ceres Fernández-Rozadilla
PBPeter Broderick
Peter Broderick
JSJames Studd
James Studd
MDMalcolm G. Dunlop
Malcolm G. Dunlop
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention.

7 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
ACAlex J. Cornish
Alex J. Cornish
AGAndreas Gruber
Andreas Gruber
BKBen Kinnersley
Ben Kinnersley
DCDaniel Chubb
Daniel Chubb
AFAnna Frangou
Anna Frangou
Richard HoulstonRichard Houlston
Richard Houlston
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2–9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichiacolipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11–13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care.

29 August 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CTClare Turnbull
Clare Turnbull
ASAmit Sud
Amit Sud
Richard HoulstonRichard Houlston
Richard Houlston